TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 121 filers reported holding TCR2 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $33,957 | -93.4% | 22,638 | -87.2% | 0.00% | – |
| Q2 2022 | $514,000 | -18.2% | 177,081 | -22.2% | 0.00% | – |
| Q1 2022 | $628,000 | -42.8% | 227,529 | -3.3% | 0.00% | – |
| Q4 2021 | $1,097,000 | -44.5% | 235,253 | +1.4% | 0.00% | -100.0% |
| Q3 2021 | $1,975,000 | -38.1% | 232,051 | +19.3% | 0.00% | 0.0% |
| Q2 2021 | $3,193,000 | -23.1% | 194,571 | +3.5% | 0.00% | -50.0% |
| Q1 2021 | $4,152,000 | -15.9% | 188,016 | +17.8% | 0.00% | 0.0% |
| Q4 2020 | $4,937,000 | +53.0% | 159,587 | +0.5% | 0.00% | +100.0% |
| Q3 2020 | $3,227,000 | +115.1% | 158,808 | +62.6% | 0.00% | 0.0% |
| Q2 2020 | $1,500,000 | +138.5% | 97,649 | +20.2% | 0.00% | – |
| Q1 2020 | $629,000 | -44.6% | 81,206 | +2.2% | 0.00% | -100.0% |
| Q4 2019 | $1,135,000 | -3.7% | 79,420 | +1.3% | 0.00% | 0.0% |
| Q3 2019 | $1,179,000 | +237.8% | 78,434 | +221.9% | 0.00% | – |
| Q2 2019 | $349,000 | – | 24,364 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |